Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by Retlaw5on May 14, 2010 9:35am
399 Views
Post# 17098722

Investor forum....

Investor forum....Now if we could only get invited to this type of forum.....

Then again....
Perhaps we have and got no luck!


ADVANCED PROTEOME THERAPEUTICS ("APC-V")

- Selected To Participate In The Life Sciences US/Canada

- Venture Capital Pipeline

     Advanced Proteome Therapeutics (the Corporation or APC) is pleased to

announce that it has been selected to participate in the upcoming Life

Sciences US/Canada Venture Capital Pipeline to be held on Thursday, May 13,

2010. The Corporation will present an overview of its platform technologies

and progress to date in applications of its Swift LinkageTM Technologies

and advancing protein conjugates in development to clinical status.

 

     The US/Canada Venture Capital Pipeline links venture capital firms

(VCs) and investment banking firms based in the U.S. with Canadian

companies seeking financing. The focus of the Pipeline event this year will

be Life Sciences.

 

     The first Pipeline was held in June 2002 and 16 more events have

occurred since that date. The event is designed to build relationships and

create business opportunities between U.S. investors and Canadian

companies. This May, multiple pre-screened Canadian Life Sciences companies

will come to Boston to meet one-on-one with U.S. investors.

 

     Since 2002, Burns & Levinson Canada Co. and Burns & Levinson LLP have

hosted Pipeline events that focus on linking venture capital firms based in

the U.S. with Canadian health and technology companies seeking financing.

By planning and facilitating one-on-one meetings, this one-day event

promotes building strategic relationships and forging lasting alliances.

The Pipeline is hosted three to four times a year at the firm's Boston, MA

office and includes additional networking opportunities during the

breakfast presentation and cocktail reception in the evening. In February

2007, this event became a co-branded partnership with Burns & Levinson LLP

and PricewaterhouseCoopers (Canada).

Bullboard Posts